Cellectis Presents Updated Clinical and Translational Data
NEW YORK, June 09, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...
Source: globenewswire.com
📰 Intermediate Dose Level News
Intermediate Dose Level News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Intermediate Dose Level. Real-time updates on events, politics, business and more.
Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
NEW YORK, June 09, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, presented today updated... | June 9, 2023
Source: marketscreener.com
Stock Market | FinancialContent Business Page
FinancialContent fully hosted finance channel
Source: financialcontent.com